Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Mar 26, 2021

Keywords

ClinConnect Summary

This clinical trial is studying new treatment options for patients with esophageal or esophagogastric junction cancer that cannot be surgically removed. The researchers are exploring the combination of chemotherapy, radiation therapy, and newer treatments like immunotherapy, which helps the body’s immune system fight cancer. The goal is to find the best approach to manage this type of cancer and improve patient outcomes.

To participate in the trial, individuals must be at least 18 years old and have a confirmed diagnosis of esophageal or esophagogastric cancer. They should also be in relatively good health, with a good performance status, meaning they can carry out daily activities. Participants will receive treatments at a specialized cancer hospital and will be closely monitored throughout the study. It’s important to note that those with certain health issues or other active cancers may not be eligible to join. If you or a loved one is interested, discussing this trial with a healthcare provider can provide more personalized information and guidance.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥18 years；
• • Esophageal or Esophagogastric cancer；
• • Histologically proven squamous cell carcinoma or adenocarcinoma in patients staged as I-IVa(AJCC 8th)；
• • Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences；
• • ECOG PS score: 0\~1；
• • Estimated survival time ≥3 months；
• • Normal organ and marrow function as defined below:Hemoglobin: greater than or equal to 100g/L ;Leukocytes: greater than or equal to 4,000 G/L; Neutrophil: greater than or equal to 2,000 G/L; Platelets: greater than or equal to 100,000/mm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater than or equal to 60 ml/min; AST/ALT: less than or equal to 2.5 times the upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5 times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than or equal to 1.5 times the upper limit；
• • Informed consent；
• Exclusion Criteria:
• • With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc；
• • Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer；
• • Existing active infection such as active tuberculosis and hepatitis；
• • History of myocardial infarction within the past 6 months or history of ventricular arrhythmia；
• • Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness History of allergic reactions attributed to paclitaxel, albumin or cisplatin；
• • Participation in other clinical trials currently or within 4 weeks of selection；
• • Pregnant or lactating females；
• • Absence of medical records.